scorecardresearch
Add as a preferred source on Google
Sunday, January 25, 2026
TopicCovishield

Topic: Covishield

Akhilesh’s claims about Covishield vaccine are baseless, says Union MoS for health SP Singh Baghel

SP chief has been raising alarm about Oxford-AstraZeneca vaccine, but Baghel points to WHO approval. Minister also confident of retaining his Agra seat, which is voting Tuesday.

How safe is AstraZeneca Covid vaccine & why there is no need to panic — some key questions answered

51 cases have been lodged in a UK court against biopharma company over claims that its Covid vaccine caused death and injury in several cases.

Don’t let anti-vaxxers weaponise AstraZeneca furore. Vaccines are safe—and we are the proof

Vaccines have eliminated two diseases—smallpox in humans and rinderpest in cattle. If they were killing one in 50,000 people, we wouldn’t be rolling them out across the globe for decades.

AstraZeneca vaccine safe, effective in kids, finds Lancet study. WHO still says for adults only

The vaccine, marketed as Covishield in India, induced antibody concentrations in children similar to those associated with high efficacy in adults, says study by UK researchers.

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

Not allowing Covishield, Covaxin retail sale meaningless. Indians need vaccines and boosters

ThePrint view on the most important issues, instantly.

On Camera

What Indira Gandhi said in her first speech as PM, 60 years ago

On 26 January 1966, Indira Gandhi delivered a speech that was broadcast over All India Radio. This was her first address to the nation after becoming India’s first woman prime minister.

India wants Canada’s resources as nations build on truce, British Columbia’s Premier says

Premier David Eby, the leader of the minerals- and gas-rich province of British Columbia, spoke with executives at Tata Steel and Reliance Industries on a trade mission to India.

US officially calls China ‘second most powerful country’, new strategy softens stand against Beijing, Moscow

New defence strategy marks clear break from Biden-era Pentagon policy, softening tone on China & Russia, while pushing allies to shoulder more responsibility with less US backing.

Non-alignment is coming back in a new avatar: Trump-peedit alliance

No nation other than China can negotiate one-on-one with Trump on an equal footing. That’s why the middle powers who so far formed the core of multilateral bodies now feel orphaned.